| Literature DB >> 29752343 |
Qian Feng1, Jing Hui1, Na Tang1, Yong-Min Liu1, Hua Zhong1, Zhen Li1, La-Mei Wang2, Yuan-Yuan Qu3, Feng-Mei Deng4, Fang He5.
Abstract
Human cytomegalovirus (HCMV) infection, chronic inflammation and oxidative stress, the renin-angiotensin system (RAS), endothelial function, and DNA methylation play roles in the pathogenesis of essential hypertension (EH); however, the mechanism by which HCMV predisposes patients to hypertension remain unclear. Our group previously demonstrated an association between EH and HCMV infection in Kazakh Chinese. Here, we investigated the relationship between HCMV infection and other clinicopathological features in 720 Kazakh individuals with or without hypertension (n=360 each; age: 18-80). Multiple linear and logistic regression analyses were used to determine the associations between HCMV infection, clinical characteristics, and EH. Notably, patients with EH, particularly those with HCMV infection, exhibited a marked increase in tumor necrosis factor-α (TNF-α) and 8-hydroxy-2-deoxyguanosine (8-OHDG) levels, but a decrease in endothelial nitric oxide synthase (eNOS) and renin levels. Similarly, elevated TNF-α and 8-OHDG levels were independent predictors of increased HCMV antibody titers, whereas eNOS and renin were negatively correlated with the latter. Moreover, serum angiotensin-converting enzyme (sACE, ACE) methylation was increased, whereas 11-β hydroxysteroid dehydrogenase 2 (HSD11β2; HSD3B2) methylation was decreased in patients with EH who were also infected with HCMV. A positive correlation between HSD3B2 methylation and HCMV IgG titer and blood pressure was additionally observed, whereas angiotensin-converting enzyme (ACE) methylation was inversely correlated with blood pressure. Collectively, these data indicate that HCMV may contribute to EH development in the Kazakh Chinese by increasing TNF-α and 8-OHDG levels, suppressing eNOS and renin, and manipulating HSD3B2 and ACE methylation.Entities:
Keywords: Essential hypertension; Human cytomegalovirus; Inflammatory response; Methylation; Oxidative stress; Renin-angiotensin system
Mesh:
Substances:
Year: 2018 PMID: 29752343 PMCID: PMC6019381 DOI: 10.1042/BSR20171522
Source DB: PubMed Journal: Biosci Rep ISSN: 0144-8463 Impact factor: 3.840
Clinicopathological characteristics of 720 Kazakh participants with and without hypertension
| Characteristics | Kazakh participants ( | ||
|---|---|---|---|
| Hypertension | Control | ||
| 360 | 360 | ||
| Males, % | 46.4 | 43.6 | 0.454 |
| Age (years) | 44.69 (11.52) | 46.05 (10.13) | 0.094 |
| Smokers, % daily | 25.3 | 23.1 | 0.486 |
| Alcohol, % daily | 31.9 | 16.9 | 0.000* |
| Vegetable, % daily | 26.4 | 14.2 | 0.000* |
| BMI (kg/m2) | 27.46 (4.66) | 24.40 (4.74) | 0.000* |
| WHR | 0.92 (0.41) | 0.86 (0.06) | 0.01* |
| SBP (mmHg) | 152.05 (22.06) | 114.33 (11.87) | 0.000* |
| DBP (mmHg) | 99.65 (13.9) | 76.08 (7.69) | 0.000* |
| MAP (mmHg) | 117.12 (15.17) | 88.83 (8.19) | 0.000* |
| FBS (mmol/l) | 6.11 (1.50) | 5.61 (0.76) | 0.000* |
| TC (mmol/l) | 5.11 (1.17) | 4.71 (1.08) | 0.000* |
| TG (mmol/l) | 1.40 (1.45) | 0.83 (0.89) | 0.000* |
| LDL-C (mmol/l) | 3.51 (0.85) | 3.00 (0.89) | 0.000* |
| HDL-C (mmol/l) | 1.42 (0.41) | 1.42 (0.29) | 0.740 |
| HCMV seropositivity, % | 96.7 | 93.3 | 0.04* |
| HCMV IgG antibody titers | 3.10 (0.93) | 3.13 (1.04) | 0.679 |
Values are expressed as means or percentages (S.D.). Hypertension was defined according to the World Health Organization guidelines.
*Statistically significant difference (P<0.05).
Clinical characteristics of 720 Kazakh study participants with and without serologic evidence of HCMV infection
| Characteristics | Kazakh participants ( | ||
|---|---|---|---|
| HCMV infection | No HCMV infection | ||
| 684 | 36 | ||
| Age (years) | 45.32 (10.70) | 46.3 (14.10) | 0.011* |
| Males | 44.3 | 61.1 | 0.048* |
| Smokers, % daily | 23.7 | 33.3 | 0.187 |
| Alcohol, % daily | 25 | 11.1 | 0.058 |
| Vegetable, % daily | 79.7 | 80.6 | 0.898 |
| BMI (kg/m2) | 26.05 (4.99) | 23.77 (3.09) | 0.013* |
| WHR | 0.89 (0.30) | 0.86 (0.10) | 0.908 |
| Hypertension, % | 50.9 | 33.3 | 0.04* |
| SBP (mmHg) | 133.27 (25.57) | 131.62 (31.41) | 0.268 |
| DBP (mmHg) | 87.99 (16.19) | 85.48 (18.08) | 1.57 |
| MAP (mmHg) | 103.08 (18.50) | 100.86 (21.98) | 1.22 |
| FBS (mmol/l) | 5.86 (1.21) | 5.93 (1.45) | 0.290 |
| TC (mmol/l) | 4.92 (1.14) | 4.57 (1.12) | 0.850 |
| TG (mmol/l) | 1.10 (1.17) | 1.30 (2.10) | 0.014* |
| LDL-C (mmol/l) | 3.27 (0.90) | 2.91 (0.86) | 0.678 |
| HDL-C (mmol/l) | 1.42 (0.35) | 1.33 (0.44) | 0.134 |
Values are expressed as means or percentages (S.D.).
*Statistically significant difference (P<0.05).
Levels of laboratory values in EH and control groups
| EH | Control | HCMV+ | HCMV− | |||
|---|---|---|---|---|---|---|
| 360 | 360 | 684 | 36 | |||
| CRP | 17.87 ± 11.64 | 15.76 ± 10.50 | 0.011* | 17.28 ± 11.22 | 8.02 ± 1.16 | 0.000* |
| TNF-α | 313.54 ± 160.92 | 290.47 ± 146.14 | 0.044* | 308.86 ± 154.98 | 171.72 ± 17.52 | 0.000* |
| NOX4 | 8.00 ± 4.48 | 5.64 ± 4.31 | 0.000* | 6.99 ± 4.60 | 3.51 ± 0.82 | 0.000* |
| 8-OHDG | 22.58 ± 17.25 | 18.88 ± 16.48 | 0.003* | 21.21 ± 17.26 | 11.73 ± 2.01 | 0.001* |
| eNOS | 17.04 ± 2.59 | 19.14 ± 6.83 | 0.000* | 18.02 ± 5.37 | 19.38 ± 2.54 | 0.132 |
| NO | 143.90 ± 55.89 | 154.66 ± 57.96 | 0.011* | 149.30 ± 57.41 | 148.92 ± 52.77 | 0.969 |
| Ang II | 1524.49 ± 328.25 | 1450.61 ± 330.79 | 0.003* | 1505.10 ± 328.50 | 1154.15 ± 171.77 | 0.000* |
| Renin | 263.03 ± 159.07 | 937.83 ± 326.23 | 0.000* | 587.23 ± 420.49 | 851.21 ± 417.82 | 0.000* |
*Statistically significant difference (P<0.05).
Linear regression analysis correlations of IgG antibody titers with laboratory values in participants
| All participants ( | Hypertension participants ( | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 1 | Model 2 | Model 3 | |||||||
| B | B | B | B | B | B | |||||||
| CRP | 1.32 | 0.002* | 1.245 | 0.004* | 1.275 | 0.003* | 1.521 | 0.021* | 1.148 | 0.09* | 1.527 | 0.024* |
| TNF-α | 16.994 | 0.003* | 12.567 | 0.032* | 12.729 | 0.030* | 5.526 | 0.544 | 1.196 | 0.898 | 6.897 | 0.458 |
| NOX4 | 0.378 | 0.027* | 0.327 | 0.059 | 0.310 | 0.072 | 0.194 | 0.445 | 0.147 | 0.573 | 0.079 | 0.765 |
| 8-OHDG | 1.880 | 0.003* | 1.753 | 0.007* | 1.728 | 0.008* | 2.473 | 0.011* | 2.494 | 0.013* | 2.289 | 0.025* |
| eNOS | −0.08 | 0.687 | −0.079 | 0.696 | −0.071 | 0.724 | −0.396 | 0.007* | −0.324 | 0.033* | −0.335 | 0.030* |
| NO | 0.965 | 0.655 | 0.585 | 0.792 | 0.715 | 0.747 | 0.093 | 0.977 | −1.147 | 0.728 | −0.85 | 0.799 |
| Ang II | 31.001 | 0.013* | 34.818 | 0.006* | 35.512 | 0.005* | 31.001 | 0.013* | 28.269 | 0.145 | 31.071 | 0.115 |
| Renin | −12.351 | 0.44* | −4.672 | 0.754 | −5.58 | 0.707 | −11.141 | 0.216 | −7.74 | 0.397 | −17.226 | 0.049 |
Model 1, unadjusted; Model 2, adjusted for gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for age.
*Statistically significant difference (P<0.05).
Binary logistic regression analysis association of laboratory values with HCMV seropositivity in all participants
| ( | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| CRP | 1.387 (1.236–1.558) | 0.000* | 1.429 (1.258–1.623) | 0.000* | 1.437 (1.263–1.635) | 0.000* |
| TNF-α | 1.022 (1.014–1.029) | 0.000* | 1.028 (1.018–1.038) | 0.000* | 1.028 (1.018–1.038) | 0.000* |
| NOX4 | 2.03 (1.517–2.715) | 0.000* | 2.011 (1.436–2.816) | 0.000* | 2.008 (1.432–2.816) | 0.000* |
| 8-OHDG | 1.299 (1.167–1.445) | 0.000* | 1.275 (1.136–1.431) | 0.000* | 1.271 (1.133–1.426) | 0.000* |
| eNOS | 0.976 (0.942–1.011) | 0.184 | 0.973 (0.934–1.013) | 0.185 | 0.974 (0.935–1.014) | 0.195 |
| NO | 0.969 (0.994–1.006) | 1 | 0.999 (0.993–1.005) | 0.773 | 1 (0.993–1.006) | 0.925 |
| Ang II | 1.003 (1.002–1.004) | 0.000* | 1.004 (1.003–1.005) | 0.000* | 1.004 (1.003–1.006) | 0.000* |
| Renin | 0.999 (0.998–0.999) | 0.000* | 0.999 (0.998–1.000) | 0.011* | 0.999 (0.998–1.000) | 0.007* |
Model 1, unadjusted; Model 2, adjusted for gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for age.
*Statistically significant difference (P<0.05).
Binary logistic regression analysis association of laboratory values with HCMV seropositivity in hypertension participants
| ( | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| CRP | 1.624 (1.224–2.154) | 0.001* | 1.976 (1.299–3.007) | 0.000* | 1.956 (1.246–3.072) | 0.004* |
| TNF-α | 1.022 (1.010–1.035) | 0.000* | 1.032 (1.012–1.052) | 0.001* | 1.048 (1.019–1.078) | 0.001* |
| NOX4 | 3.536 (1.829–6.838) | 0.000* | 4.038 (1.731–9.418) | 0.001* | 3.616 (1.534–8.527) | 0.003* |
| 8-OHDG | 1.352 (1.136–1.610) | 0.001* | 1.485 (1.157–1.908) | 0.002* | 1.569 (1.181–2.084) | 0.002* |
| eNOS | 0.661 (0.520–0.839) | 0.001* | 0.665 (0.491–0.900) | 0.008* | 0.671 (0.490–0.917) | 0.012* |
| NO | 1.002 (0.992–1.013) | 0.686 | 1.001 (0.988–1.014) | 0.884 | 1.001 (0.987–1.015) | 0.9 |
| Ang II | 1.003 (1.001–1.005) | 0.000* | 1.004 (1.002–1.007) | 0.001* | 1.005 (1.002–1.007) | 0.002* |
| Renin | 0.996 (0.992–1.000) | 0.036* | 0.997 (0.993–1.001) | 0.184 | 0.995 (0.990–1.000) | 0.045* |
Model 1, unadjusted; Model 2, adjusted for gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for age.
*Statistically significant difference (P<0.05).
Linear regression analysis correlations of laboratory values with BP in all participants
| ( | SBP | DBP | MAP | ||||
|---|---|---|---|---|---|---|---|
| B | B | B | |||||
| CRP | Model 1 | 1.193 | 0.000* | 0.565 | 0.000* | 0.775 | 0.000* |
| Model 2 | 1.060 | 0.000* | 0.497 | 0.000* | 0.684 | 0.000* | |
| Model 3 | 1.091 | 0.000* | 0.507 | 0.000* | 0.702 | 0.000* | |
| TNF-α | Model 1 | 0.018 | 0.004* | 0.006 | 0.124 | 0.010 | 0.026* |
| Model 2 | 0.015 | 0.011* | 0.004 | 0.269 | 0.008 | 0.069 | |
| Model 3 | 0.016 | 0.006* | 0.004 | 0.239 | 0.008 | 0.053 | |
| NOX4 | Model 1 | 0.574 | 0.007* | 0.412 | 0.002* | 0.466 | 0.002* |
| Model 2 | 0.318 | 0.104 | 0.202 | 0.111 | 0.241 | 0.092 | |
| Model 3 | 0.346 | 0.078 | 0.210 | 0.098 | 0.255 | 0.075 | |
| 8-OHDG | Model 1 | 0.227 | 0.000* | 0.120 | 0.001* | 0.156 | 0.000* |
| Model 2 | 0.184 | 0.000* | 0.089 | 0.008* | 0.184 | 0.000* | |
| Model 3 | 0.196 | 0.000* | 0.093 | 0.006* | 0.127 | 0.001* | |
| eNOS | Model 1 | −1.117 | 0.000* | −0.613 | 0.000* | −0.781 | 0.000* |
| Model 2 | −0.877 | 0.000* | −0.462 | 0.000* | −0.601 | 0.000* | |
| Model 3 | −0.882 | 0.000* | −0.464 | 0.000* | −0.603 | 0.000* | |
| NO | Model 1 | −0.002 | 0.906 | −0.013 | 0.208 | −0.010 | 0.432 |
| Model 2 | 0.003 | 0.869 | −0.010 | 0.304 | −0.006 | 0.595 | |
| Model 3 | 0.003 | 0.851 | −0.010 | 0.309 | −0.006 | 0.607 | |
| Ang II | Model 1 | 0.028 | 0.000* | 0.011 | 0.000* | 0.017 | 0.000* |
| Model 2 | 0.022 | 0.000* | 0.009 | 0.000* | 0.013 | 0.000* | |
| Model 3 | 0.023 | 0.000* | 0.009 | 0.000* | 0.014 | 0.000* | |
| Renin | Model 1 | −0.05 | 0.000* | −0.028 | 0.000* | −0.035 | 0.000* |
| Model 2 | −0.047 | 0.000* | −0.027 | 0.000* | −0.034 | 0.000* | |
| Model 3 | −0.048 | 0.000* | −0.027 | 0.000* | −0.034 | 0.000* | |
Model 1, unadjusted; Model 2, adjusted for age, gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for IgG antibody titers.
*Statistically significant difference (P<0.05).
Linear regression analysis correlations of laboratory values with BP in hypertension participants
| ( | SBP | DBP | MAP | ||||
|---|---|---|---|---|---|---|---|
| B | B | B | |||||
| CRP | Model 1 | 1.335 | 0.000* | 0.631 | 0.000* | 0.866 | 0.000* |
| Model 2 | 1.204 | 0.000* | 0.596 | 0.000* | 0.799 | 0.000* | |
| Model 3 | 1.229 | 0.000* | 0.609 | 0.000* | 0.816 | 0.000* | |
| TNF-α | Model 1 | 0.060 | 0.000* | 0.021 | 0.000* | 0.034 | 0.000* |
| Model 2 | 0.047 | 0.000* | 0.018 | 0.000* | 0.027 | 0.000* | |
| Model 3 | 0.047 | 0.000* | 0.018 | 0.000* | 0.027 | 0.000* | |
| NOX4 | Model 1 | −0.482 | 0.063 | −0.271 | 0.098 | 0.056 | |
| Model 2 | −0.306 | 0.196 | −0.277 | 0.091 | −0.287 | 0.100 | |
| Model 3 | −0.304 | 0.200 | −0.276 | 0.093 | 0.285 | 0.102 | |
| 8-OHDG | Model 1 | 0.020 | 0.773 | 0.018 | 0.673 | 0.018 | 0.691 |
| Model 2 | 0.066 | 0.282 | 0.036 | 0.391 | 0.046 | 0.304 | |
| Model 3 | 0.071 | 0.248 | 0.039 | 0.360 | 0.050 | 0.272 | |
| eNOS | Model 1 | −0.332 | 0.461 | −0.535 | 0.059 | −0.467 | 0.131 |
| Model 2 | −0.355 | 0.380 | −0.513 | 0.067 | −0.461 | 0.121 | |
| Model 3 | −0.388 | 0.341 | −0.535 | 0.058 | −0.486 | 0.105 | |
| NO | Model 1 | −0.016 | 0.450 | −0.005 | 0.729 | 0.002 | 0.877 |
| Model 2 | 0.015 | 0.429 | −0.007 | 0.546 | −6.333 × 10−5 | 0.996 | |
| Model 3 | 0.015 | 0.434 | −0.008 | 0.560 | −1.633 × 10−4 | 0.991 | |
| Ang II | Model 1 | 0.013 | 0.000* | 0.002 | 0.475 | 0.005 | 0.030* |
| Model 2 | 0.011 | 0.001* | 0.001 | 0.540 | 0.005 | 0.051 | |
| Model 3 | 0.011 | 0.000* | 0.001 | 0.515 | 0.005 | 0.045* | |
| Renin | Model 1 | −0.097 | 0.000* | −0.035 | 0.000* | −0.055 | 0.000* |
| Model 2 | −0.085 | 0.000* | −0.035 | 0.000* | −0.051 | 0.000* | |
| Model 3 | −0.086 | 0.000* | −0.036 | 0.000* | −0.051 | 0.000* | |
Model 1, unadjusted; Model 2, adjusted for age, gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for IgG antibody titers.
*Statistically significant difference (P<0.05).
Binary logistic regression analysis association of laboratory values with hypertension
| ( | Model 1 | Model 2 | Model 3 | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| CRP | 1.017 (1.004–1.031) | 0.012* | 1.009 (0.994–1.025) | 0.232 | 1.011 (0.995–1.026) | 0.178 |
| TNF-α | 1.001 (1.000–1.002) | 0.045* | 1.001 (1.000–1.002) | 0.029* | 1.001 (1.000–1.002) | 0.023* |
| NOX4 | 1.136 (1.094–1.180) | 0.000* | 1.123 (1.078–1.171) | 0.000* | 1.126 (1.080–1.174) | 0.000* |
| 8-OHDG | 1.014 (1.004–1.023) | 0.004* | 1.012 (1.001–1.022) | 0.027* | 1.012 (1,002–1.023) | 0.019* |
| eNOS | 0.827 (0.782–0.874) | 0.000* | 0.849 (0.798–0.903) | 0.000* | 0.846 (0.795–0.900) | 0.000* |
| NO | 0.997 (0.994–0.999) | 0.012* | 0.996 (0.993–0.999) | 0.009* | 0.996 (0.993–0.999) | 0.009* |
| Ang II | 1.001 (1.000–1.001) | 0.003* | 1 (1.000–1.001) | 0.219 | 1 (1.000–1.001) | 0.163 |
| Renin | 0.976 (0.971–0.981) | 0.000* | 0.972 (0.965–0.979) | 0.000* | 0.972 (0.965–0.979) | 0.000* |
Model 1, unadjusted; Model 2, adjusted for age, gender, smoking, alcohol consumption, vegetable intake, BMI, WHR, FBS, TC, TG, LDL-C, and HDL-C; Model 3, further adjusted for IgG antibody titers.
*Statistically significant difference (P<0.05).
Figure 1Gene methylation levels in EH (n=6) and control groups (n=4) (%); HCMV+ represents HCMV seropositivity; HCMV− represents HCMV seronegativity
(A) Serum ACE (sACE) and HSD11β2 gene methylation in the EH group compared with that in the control group (P<0.05). (B) sACE gene methylation in HCMV seropositive subjects relative to HCMV seronegative subjects in the two groups (P<0.05). (C) HSD11β2 gene methylation in HCMV seropositive subjects relative to HCMV seronegative subjects in the two groups (P<0.05).
Levels of gene methylation in EH and control group
| EH | Control | HCMV infection | No HCMV infection | ||
|---|---|---|---|---|---|
| 20 | 10 | 22 | 8 | ||
| ADD1 | CpG1 | 2.80 ± 1.11 | 3.00 ± 0.81 | 2.77 ± 1.066 | 3.13 ± 0.835 |
| CpG2 | 2.15 ± 1.27 | 2.20 ± 1.23 | 2.09 ± 1.306 | 2.375 ± 1.061 | |
| CpG3 | 11.35 ± 3.17 | 11.80 ± 1.93 | 11.41 ± 3.081 | 11.75 ± 2.188 | |
| CpG4 | 5.15 ± 1.14 | 5.20 ± 0.63 | 5.04 ± 1.069 | 5.62 ± 0.518 | |
| CpG5 | 7.95 ± 1.82 | 8.60 ± 1.78 | 8.14 ± 2.031 | 8.25 ± 1.035 | |
| SULF1 | CpG1 | 15.85 ± 2.70 | 18.40 ± 4.25 | 16.877 ± 3.308 | 16.51 ± 4.036 |
| CpG2 | 21.65 ± 3.31 | 23.80 ± 4.61 | 22.05 ± 3.946 | 23.25 ± 3.694 |
Figure 2Correlations between IgG antibody titers and gene methylation level in EH and control groups
(A) Correlation between sACE methylation level and IgG antibody titers in all participants (n=10). (B) Correlation between HSD11β2 methylation level and IgG antibody titers in all participants (n=10). (C) Correlation between sACE methylation level and IgG antibody titers in the EH group (n=6). (D) Correlation between HSD11β2 methylation level and IgG antibody titers in the EH group (n=6).
Figure 3Correlations between gene methylation level and BP in participants
(a) Correlations between gene methylation level and BP in all participants (n=10). sACE, angiotensin converting enzyme; HSD11β2, 11-β hydroxy steroid dehydrogenase 2. (A) Correlation between sACE methylation level and SBP in all participants. (B) Correlation between sACE methylation level and DBP in all participants. (C) Correlation between sACE methylation level and MAP in all participants. (D) Correlation between HSD11β2 methylation level and SBP in all participants. (E) Correlation between HSD11β2 methylation level and DBP in all participants. (F) Correlation between HSD11β2 methylation level and MAP in all participants. (b) Correlation between gene methylation levels and BP in the EH group (n=6). sACE, angiotensin converting enzyme; HSD11β2, 11-β hydroxy steroid dehydrogenase 2. (A) Correlation between sACE methylation level and SBP in the EH group. (B) Correlation between sACE methylation level and DBP in the EH group. (C) Correlation between sACE methylation level and MAP in the EH group. (D) Correlation between HSD11β2 methylation level and SBP in the EH group. (E) Correlation between HSD11β2 methylation level and DBP in the EH group. (F) Correlation between HSD11β2 methylation level and MAP in the EH group.